{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/obesity/prescribing-information/orlistat/","result":{"pageContext":{"chapter":{"id":"9f3444a7-5139-58ee-9fdf-470378719d4c","slug":"orlistat","fullItemName":"Orlistat","depth":2,"htmlHeader":"<!-- begin field 4acb7aa1-2e94-4c06-9aca-24df4b179ff6 --><h2>Orlistat</h2><!-- end field 4acb7aa1-2e94-4c06-9aca-24df4b179ff6 -->","summary":"","htmlStringContent":"<!-- begin item c2043e35-1d57-4b6e-9706-0155e481c79b --><!-- end item c2043e35-1d57-4b6e-9706-0155e481c79b -->","topic":{"id":"c301533a-3c5f-5238-aac1-4bf163fabdf2","topicId":"ce3a3429-b3d0-4c54-8025-abb6e33dff88","topicName":"Obesity","slug":"obesity","lastRevised":"Last revised in December 2017","chapters":[{"id":"dd66ad3d-4814-5adc-92fb-39e3b4d8f788","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"0fa3d01a-4842-5ec2-b85f-638b92e3ef14","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"64d9ae78-8203-5176-bef3-411c488b93dc","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"892bc984-b7ae-5830-91da-e570afd541ed","slug":"changes","fullItemName":"Changes"},{"id":"322163e5-1cb7-5dc8-b9ca-874d4fdb1a44","slug":"update","fullItemName":"Update"}]},{"id":"ef9a094b-abce-5a97-bee5-98c4986de194","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"4772dece-06ea-5147-bc24-b36aae1dd6a3","slug":"goals","fullItemName":"Goals"},{"id":"57961a43-ade1-5671-bb4f-44614134ded9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"91fec363-e9d2-57df-a40e-dbbfce99eb80","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6f66b98c-4b76-5bad-a30b-597d598b7ff1","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"820d050d-9427-5bcb-b0b5-6f7e333a2056","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ef76ada9-ccbd-5dcc-80d5-10c669767ffb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"fef14215-12d6-5f3e-893f-df50af3914c7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8cbe6b8e-e49a-5e5a-a6a9-a8418bd1db6d","slug":"definition","fullItemName":"Definition"},{"id":"68511bf4-0ad9-5032-9404-0d9c659a09fd","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"ae570c8c-13b3-5f83-a6cd-20cbd1e99dfd","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d3a07f9f-8796-50a6-9b7e-be818027fc9d","slug":"complications","fullItemName":"Complications"},{"id":"b543814e-2966-5638-8ec9-7767c793f4fb","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ab0c929a-0525-5cc1-86b6-65b4e5658543","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d7700030-6b9b-5b4d-ab70-25bd30339658","slug":"identification-classification","fullItemName":"Identification and classification"}]},{"id":"04af64f4-0f60-5070-aaa3-0bdd9e7dd6f2","fullItemName":"Management","slug":"management","subChapters":[{"id":"e4b24d9e-7f0e-59a8-a645-c066aea705e7","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"495b0383-35b9-5867-bb77-aaaa0d5fdf66","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9f3444a7-5139-58ee-9fdf-470378719d4c","slug":"orlistat","fullItemName":"Orlistat"}]},{"id":"e90e6f47-5738-5130-8d94-294893d8720d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"a9337ec8-ca00-5ca7-a462-63a97314e80e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9e1d9ebc-ef23-5b61-bec5-4e83c2199fc4","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"da92e3a5-0e63-5c04-b64f-d5488b75e819","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1780d629-8ef2-59a3-872b-3935a6ed76ce","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"748e81ae-7a14-5115-91a0-58f82c43a92f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"542915ac-f7c9-5a27-a026-35779f6e1dc9","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"fb8b0b27-c7ac-5950-ac6c-7ae225054a3d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"495b0383-35b9-5867-bb77-aaaa0d5fdf66","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"2eef09e9-96e7-5e81-bcc8-5d6c18de776e","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field c6eaee00-06b7-4064-950c-79682f430e69 --><h3>What are the contraindications and cautions for orlistat?</h3><!-- end field c6eaee00-06b7-4064-950c-79682f430e69 -->","summary":"","htmlStringContent":"<!-- begin item a752690e-1c36-4d8e-8407-fd1ee41308b6 --><!-- begin field 3d8289f7-fa79-4cef-8fee-40e4f92eea16 --><ul><li><strong>Do not prescribe orlistat to:</strong><ul><li>People with chronic malabsorption syndrome or cholestasis — dietary absorption of fat is already impaired in these people.</li><li>Breastfeeding women — it is not known whether orlistat is secreted into human milk.</li></ul></li><li><strong>Prescribe orlistat with caution to people with:</strong><ul><li>Chronic kidney disease (CKD) and/or volume depletion — the use of orlistat may be associated with hyperoxaluria and oxalate nephropathy leading sometimes to renal failure. This risk is increased in people with underlying CKD and/or volume depletion.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/obesity/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obesity/references/\">BNF 74, 2017</a>] </p><!-- end field 3d8289f7-fa79-4cef-8fee-40e4f92eea16 --><!-- end item a752690e-1c36-4d8e-8407-fd1ee41308b6 -->","subChapters":[]},{"id":"fa84453c-fa31-5f22-a8c6-40c7c67fed92","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field fa1a15b5-69c9-4aba-9873-ea8f2bcc561e --><h3>What adverse effects are associated with orlistat?</h3><!-- end field fa1a15b5-69c9-4aba-9873-ea8f2bcc561e -->","summary":"","htmlStringContent":"<!-- begin item 7bc667c8-3a01-40ac-bb43-a2bb13e95428 --><!-- begin field dde0de3f-62e7-48f0-acbe-7175d1b62a00 --><ul><li><strong>Very common and common adverse effects include:</strong><ul><li>Gastrointestinal adverse effects, for example, oily spotting, abdominal discomfort, abdominal pain, flatulence, faecal urgency, faecal incontinence, and fatty stools. These usually reduce with continued use of orlistat and can often be reduced by limiting fat intake.</li><li>Headache.</li><li>Respiratory infections.</li><li>Urinary tract infection.</li><li>Hypoglycaemia.</li><li>Anxiety.</li><li>Gingival and tooth disorders.</li><li>Fatigue.</li><li>Menstrual disturbances.</li></ul></li><li><strong>Absorption of fat-soluble vitamins (A, D, E, K, and beta-carotene) may be impaired in people taking orlistat. </strong>However, in most people levels remain within the normal range.<ul><li>Advise people to have a diet that is rich in fruit and vegetables and consider the use of a multivitamin supplement.</li><li>Multivitamin supplements should be taken at least two hours after taking orlistat.</li></ul></li><li><strong>Very rarely (less than 1/10,000) hepatitis and cholelithiasis have been reported [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obesity/references/\">MHRA, 2010</a>].</strong><ul><li>The European Medicines Agency (EMA) reviewed the safety of orlistat following concerns about the possible risk of hepatic injury and concluded that the benefits of orlistat outweigh the risks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obesity/references/\">EMA, 2012</a>].</li><li>Advise the person to stop taking orlistat and seek medical assistance if they develop symptoms of hepatitis (yellowing skin and eyes, itching, dark-coloured urine, stomach pain and liver tenderness).</li></ul></li><li><strong>Bullous eruptions, diverticulitis, hypothyroidism, oxalate nephropathy, and rectal bleeding may also occur, </strong>but the frequency is unknown.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/obesity/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obesity/references/\">BNF 74, 2017</a>] </p><!-- end field dde0de3f-62e7-48f0-acbe-7175d1b62a00 --><!-- end item 7bc667c8-3a01-40ac-bb43-a2bb13e95428 -->","subChapters":[]},{"id":"2c572675-9287-53ef-a659-3d5f0fbf8c73","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 7929da95-3acd-40b4-8ae0-25c65bf673d5 --><h3>What key drug interactions are associated with orlistat?</h3><!-- end field 7929da95-3acd-40b4-8ae0-25c65bf673d5 -->","summary":"","htmlStringContent":"<!-- begin item e9e3bb9a-03e2-46ee-84cf-f307431cfbe2 --><!-- begin field 75707bd2-bc0c-476c-b2be-c87d9aeaa016 --><ul><li><strong>Drug interactions associated with orlistat include:</strong><ul><li><strong>Acarbose</strong> — the manufacturer of orlistat recommends that concurrent treatment with acarbose should be avoided due to the absence of pharmacokinetic interaction studies.</li><li><strong>Antiepileptic drugs </strong>— orlistat may reduce the absorption of antiepileptic drugs. Loss of seizure control has been reported during concurrent treatment with orlistat and sodium valproate or lamotrigine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obesity/references/\">MHRA, 2010</a>].<ul><li>Advise the person to consider taking the antiepileptic drug at a different time to orlistat (such as 2 hours after a dose of orlistat or at bedtime) to reduce the risk of this interaction.</li><li>Monitor the person for possible changes in the frequency and/or severity of convulsions.</li></ul></li><li><strong>Amiodarone </strong>— a slight decrease in plasma levels of amiodarone, when given as a single dose, has been observed in a limited number of healthy volunteers who received orlistat concomitantly. The clinical relevance of this effect remains unknown but may become clinically relevant in some cases.<ul><li>In people receiving concomitant amiodarone treatment, reinforcement of clinical and ECG monitoring is warranted.</li></ul></li><li><strong>Ciclosporin </strong>— orlistat reduces plasma levels of ciclosporin, leading to a decrease of immunosuppressive efficacy.<ul><li>Concurrent use is not recommended, but if it is unavoidable, monitor ciclosporin levels frequently when starting or stopping orlistat. Monitor ciclosporin blood levels until stabilized.</li></ul></li><li><strong>Fat-soluble vitamins </strong>— the absorption of vitamins A, D, E, K, and beta-carotene may be impaired in people taking orlistat; however, in most people levels remain within the normal range.<ul><li>Advise people to have a diet that is rich in fruit and vegetables and to consider the use of a multivitamin supplement. Multivitamin supplements should be taken at least two hours after taking orlistat.</li><li>In people taking warfarin, be aware that orlistat may reduce the absorption of vitamin K (which is fat soluble) with the result that a lower dose of warfarin is required. Monitor international normalised ratio (INR) closely, especially when starting or stopping treatment with orlistat [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obesity/references/\">Preston, 2016</a>].</li></ul></li><li><strong>Levothyroxine</strong> — orlistat may reduce the absorption of levothyroxine, leading to reduced control of hypothyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obesity/references/\">MHRA, 2010</a>].<ul><li>Advise the person to consider taking levothyroxine at a different time to orlistat to reduce the interaction (such as 2 hours after a dose of orlistat or at bedtime).</li></ul></li><li><strong>Oral anticoagulants </strong>— decreased prothrombin, increased INR, and unbalanced anticoagulant treatment, resulting in variations of haemostatic parameters have been reported when warfarin (or other anticoagulants) is given in combination with orlistat.<ul><li>Monitor INR closely during concurrent treatment.</li></ul></li><li><strong>Other medications </strong>— there are some case reports of reduced efficacy of antiretrovirals, antidepressants, antipsychotics (including lithium), and benzodiazepines coincidental to the initiation of orlistat treatment in previously well-controlled people.<ul><li>Orlistat treatment should only be initiated after careful consideration of the possible impact in these people.</li></ul></li><li><strong>Oral contraceptives</strong> — no direct interaction between oral contraceptives and orlistat has been demonstrated in specific drug-drug interaction studies. However, orlistat may indirectly reduce the availability of oral contraceptives through its action on the gastrointestinal tract.<ul><li>If a woman experiences severe diarrhoea whilst taking orlistat an additional contraceptive method is recommended.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/obesity/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obesity/references/\">BNF 74, 2017</a>]</p><!-- end field 75707bd2-bc0c-476c-b2be-c87d9aeaa016 --><!-- end item e9e3bb9a-03e2-46ee-84cf-f307431cfbe2 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}